Willingness to risk death endpoint in HIV cure-related research with otherwise healthy volunteers is misleading.

作者: Karine Dubé , Lynda Dee

DOI: 10.1016/S2055-6640(20)30021-2

关键词: Value (ethics)Family medicineRelated researchScrutinyRisk of deathMedicineHuman immunodeficiency virus (HIV)PrudencePublic trustHealthy volunteers

摘要: Abstract This viewpoint article critiques two recent articles examining ‘willingness to risk death’ advance HIV cure-related research. The endpoint sends the wrong signal research community about ongoing in otherwise healthy volunteers living with HIV. Socio-behavioural scientists have examined acceptability of a 99% death scenario, which is unrealistic and would not be acceptable by current regulatory ethical standards. We believe that field needs robust relevant socio-behavioural reflecting biomedical trials. These studies will need withstand scrutiny if cure or remission regimens are proceed licensing stage. must continue protect public trust sustain societal value generated such call for utmost prudence designing trials as well setting up experiments related these complex

参考文章(36)
Joanna Różyńska, On the Alleged Right to Participate in High-Risk Research Bioethics. ,vol. 29, pp. 451- 461 ,(2015) , 10.1111/BIOE.12146
Véronique Avettand-Fenoel, Nizar Mahlaoui, Marie-Laure Chaix, Catherine Milliancourt, Marianne Burgard, Marina Cavazzana-Calvo, Christine Rouzioux, Stéphane Blanche, Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART. AIDS. ,vol. 21, pp. 776- 777 ,(2007) , 10.1097/QAD.0B013E3280B01836
David B. Resnik, Limits on risks for healthy volunteers in biomedical research Theoretical Medicine and Bioethics. ,vol. 33, pp. 137- 149 ,(2012) , 10.1007/S11017-011-9201-1
David DiGiusto, Rodica Stan, Amrita Krishnan, Haitang Li, John Rossi, John Zaia, Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice Viruses. ,vol. 5, pp. 2898- 2919 ,(2013) , 10.3390/V5112898
Lambros Kordelas, Jens Verheyen, Stefan Esser, Shift of HIV Tropism in Stem-Cell Transplantation with CCR5 Delta32 Mutation New England Journal of Medicine. ,vol. 371, pp. 880- 882 ,(2014) , 10.1056/NEJMC1405805
Kristina Allers, Gero Hütter, Jörg Hofmann, Christoph Loddenkemper, Kathrin Rieger, Eckhard Thiel, Thomas Schneider, Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation Blood. ,vol. 117, pp. 2791- 2799 ,(2011) , 10.1182/BLOOD-2010-09-309591
Nir Eyal, Daniel R Kuritzkes, Challenges in clinical trial design for HIV-1 cure research. The Lancet. ,vol. 382, pp. 1464- 1465 ,(2013) , 10.1016/S0140-6736(13)62040-1
Jeremy Sugarman, Sharon R Lewin, Timothy J Henrich, Thomas A Rasmussen, Ethics of ART interruption after stem-cell transplantation The Lancet HIV. ,vol. 3, pp. e8- e10 ,(2016) , 10.1016/S2352-3018(15)00248-9
M. Delaney, The Case for Patient Access to Experimental Therapy The Journal of Infectious Diseases. ,vol. 159, pp. 416- 419 ,(1989) , 10.1093/INFDIS/159.3.416
Sara Gianella, Jeff Taylor, Timothy R. Brown, Andy Kaytes, Cristian L. Achim, David J. Moore, Susan J. Little, Ronald J. Ellis, Davey M. Smith, Can research at the end of life be a useful tool to advance HIV cure AIDS. ,vol. 31, pp. 1- 4 ,(2017) , 10.1097/QAD.0000000000001300